By Max Clarke
A surge order intake during the 12 months ending March 31st has seen Oxford Instruments (LSE: OXIG) boost its revenue by a staggering 24%.
In recent years, the high-tech business has witnessed exponential growth and yesterday announced the acquisition of a further 2 tech start-ups for more than £40 million: Omicron NanoTechnology GmbH and Omniprobe, Inc.
The acquisition will see the Oxford University science off-spin further increase its influence across the plasma, nanoscience, and superconductor fields.
"It is now five years since we announced our plan to double the size of Oxford Instruments and significantly improve our margins,” said the group’s chairman, Nigel Keen. “Our successful implementation of this strategy is reflected by this set of results, the strongest performance in the Group’s 51 year history. Our new three year plan, to target 14% annual revenue growth and ROS of 14% by 2014, sets the framework for delivering sustained shareholder value driven by strong organic growth, continuous efficiency improvements and targeted acquisitions."
Join us on